To The Moon

[The Fed has the economy's back in 2024, says Wharton's Jeremy Siegel] Jeremy Siegel, Wharton Professor, joins 'Closing Bell' to discuss the markets, equities and his Fed outlook. $S&P 500(.SPX)$

1. Pharma stocks $Regeneron Pharmaceuticals(REGN)$ and $Vertex Pharmaceuticals(VRTX)$ hit new high of $853.97 and $374.45 respectively. $Regeneron Pharmaceuticals(REGN)$ three core value drivers are its eye disease drug Eylea (now available in a high-dose form), immunology drug Dupixent, and anti-cancer therapy Libtayo. FDA approved its high-dose Eylea in August. $Vertex Pharmaceuticals(VRTX)$ is striving to develop treatments for APOL1-mediated kidney disease, non-opioid pain medications, rare blood disorders, and diabetes. 2. Insurance stocks $Arch Capital(ACG

On Fri, 13 Oct 2023 — $JPMorgan Chase(JPM)$, $Wells Fargo(WFC)$ and $Citigroup(C)$ have released their Q3 2023 earnings. Despite all the challenges faced by the financial sector, the 3 banks managed to report profits. JPMorgan Chase & Co. reported a profit of $13.15 billion, or $4.33 a share, YoY. Wells Fargo & Company reported a profit of $6.04 billion, or $1.38 a share, YoY. Citigroup Inc.reported a profit of $5.2 billion, or $2.85 a share, YoY. On Tue, 17 Oct 2023 $Bank of America(BAC)$ will be reporting its Q3 2023 quarterly earnings. I came across a post by Barron (see below), that I think is insightful and remind

Hello, fellow tigers! Today, I want to share how I celebrated $Bank of America(BAC)$ recent third-quarter earnings report with a well-timed strangle position. Q3 Highlights In the third quarter, BAC reported earnings per share (EPS) of $0.90, surpassing the analyst consensus estimate of $0.83. Additionally, the bank's revenue for the quarter came in at $25.2 billion, slightly ahead of the consensus estimate of $25.13 billion. These impressive results provided a strong foundation for my investment strategy. BAC Daily Chart With the stock price that closed at $26.99, it's important to note that BAC had faced some challenges, with a -14.83% decline over the last three months and a -22.62% dip in the past year. Despite these hurdles, I saw an opportuni